Peptide Bloodwork & Monitoring Guide: Which Labs to Run and Why

Peptide protocols change biology — that's the point. The cheap and obvious way to know whether they're doing what you think and not doing something you don't want is bloodwork. Most off-label peptide users skip this step. Here's the class-by-class minimum.

Baseline labs everyone should have before any peptide protocol

Before starting any peptide, get these in hand. They cost ~$150–250 with most direct-to-consumer labs and serve as the comparison point for everything that follows.

• Comprehensive metabolic panel (CMP) — kidney, liver, electrolytes, glucose
• Lipid panel — total cholesterol, LDL, HDL, triglycerides
• HbA1c and fasting glucose — three-month and acute glucose state
• CBC with differential — anemia, immune cell counts
• TSH, free T4, free T3 — thyroid baseline
• Vitamin D (25-OH) and B12 — frequently deranged, easy to fix
• hsCRP — systemic inflammation baseline
• IGF-1 — required if you're touching anything in the GH axis

If you're male and over 40: add PSA, total testosterone, free testosterone, SHBG, estradiol (sensitive assay).

If you're female and over 40: add estradiol, FSH, LH (cycle day matters), progesterone, DHEA-S.

GH-axis peptides: Sermorelin, Tesamorelin, CJC-1295, Ipamorelin, GHRP-2/6, Hexarelin

The point of these peptides is to elevate GH and IGF-1 within physiological pulse limits. The labs are confirmatory and risk-monitoring.

Track:

• IGF-1 at baseline, 6 weeks in, then quarterly. Should rise into the upper-normal range for your age. If it doesn't rise, the peptide isn't doing its primary job (or your supply is bunk). If it crosses age-adjusted upper limit, dose down.
• Fasting glucose and HbA1c at baseline, 6–8 weeks, then every 3 months. GH transiently worsens insulin sensitivity. If A1C climbs above 5.7, reassess the protocol.
• Lipid panel at baseline and quarterly. GH can affect lipids modestly; the direction varies.
• Comprehensive metabolic panel quarterly — kidney function, liver enzymes.

Watch for: edema, joint pain, carpal tunnel symptoms, persistent paresthesias. These suggest IGF-1 is too high regardless of the lab number.

For men over 50: add PSA quarterly. The IGF-1/cancer relationship is theoretical but not zero, and prostate biology is IGF-1-sensitive.

GLP-1 / GIP peptides: Semaglutide, Tirzepatide, Liraglutide, Retatrutide, Cagrilintide

The most-prescribed peptide class in 2026 has the most established monitoring playbook because the FDA labels carry it.

Track:

• HbA1c baseline, 12 weeks, then every 3 months. The therapeutic mechanism is glucose-related; non-diabetic users should still see A1C drop modestly.
• Lipase and amylase at baseline. The pancreatitis signal in GLP-1 trials is small but real. New-onset severe abdominal pain with elevated lipase = stop the peptide and seek evaluation.
• Comprehensive metabolic panel including kidney function quarterly. AKI from severe GI side effects (vomiting, dehydration) is the main mechanistic concern.
• TSH at baseline. The medullary thyroid carcinoma boxed warning is largely from rodent data, but personal or family history of MEN2/MTC is a contraindication regardless.
• Bone density consideration with extended weight-loss protocols. DEXA at baseline if you're post-menopausal or otherwise high-fracture-risk.

Watch for: severe abdominal pain (pancreatitis), persistent vomiting (gastroparesis), gallbladder symptoms (right upper quadrant pain), and unintentional muscle loss.

Healing peptides: BPC-157, TB-500, Pentosan Polysulfate

Less to monitor mechanistically but the safety baseline still matters because the peptides themselves have thin human safety data.

Track:

• CBC with differential baseline and quarterly.
• hsCRP baseline and 6–8 weeks in. Should drop if there is active inflammation being addressed.
• Comprehensive metabolic panel baseline and quarterly.

Watch for: unusual bruising or bleeding (Pentosan Polysulfate carries a documented bleeding-risk signal because of its heparin-adjacent mechanism), unexplained fatigue, new pigmentary maculopathy on extended PPS use.

Longevity peptides: Epitalon, Thymalin, Thymosin Alpha-1, MOTS-c, SS-31, FOXO4-DRI

The mechanistic targets are diffuse and the trial data is thin. Lab tracking is more about ruling out adverse effects than confirming target hits.

Track:

• Standard baseline panel quarterly.
• hsCRP, IGF-1, DHEA-S as biomarkers of "biological age" if that's the framing.
• Epigenetic age testing (DunedinPACE, GrimAge) — useful as a multi-year baseline-and-follow-up if you can afford the $200–500 each. Single readings have meaningful noise.
• Sex hormones if hormonal effects are being claimed for the peptide.

Watch for: anything unusual. The trial data is so thin that anomalies in routine labs deserve close attention.

Sexual function peptides: PT-141 / Bremelanotide, Melanotan II, Kisspeptin-10

Track:

• Blood pressure — PT-141 raises BP transiently. If you have uncontrolled hypertension, this is the contraindication.
• CBC baseline — Melanotan II's case reports of melanoma justify watching pigmented lesions clinically rather than via labs, but the standard CBC catches gross abnormalities.

Watch for: new or changing moles (Melanotan II specifically), persistent erection lasting >4 hours (priapism — emergency), severe nausea or BP elevation.

Cosmetic peptides: GHK-Cu, Argireline, Matrixyl, SNAP-8

Topical use carries no required lab monitoring. Patch testing and routine dermatologic follow-up if you have sensitive or reactive skin is the relevant level of attention.

How to read the numbers

A peptide protocol that's "working" should produce predictable directional changes in the labs that match its mechanism. If labs don't move in the expected direction:

1. Confirm the peptide is real (vendor, reconstitution, dose accuracy)
2. Review timing of the draw (IGF-1 fluctuates less than GH, but not zero)
3. Consider dose, frequency, or stack interactions

If labs move but in the wrong direction (rising A1C on a GLP-1, falling IGF-1 on a GH peptide), something is wrong with either the protocol or the peptide.

What this guide is not

This is not medical advice. The labs above are oriented toward off-label peptide use; if you have an actual medical indication, your clinician's monitoring plan supersedes this. Use this as a structured checklist for the conversation, not a substitute for it.

Bottom line

Bloodwork is the cheapest way to verify a peptide protocol is doing what you think and not doing what you don't. The cost of a comprehensive panel is small relative to the cost of the peptides themselves. Skipping it means you're running an experiment without an instrument.